Abstract:
Cathepsin L (CatL) is a lysosomal cysteine protease primarily involved in the terminal degradation of intracellular and endocytosed proteins. More specifically, in humans, CatL has been implicated in cancer progression and metastasis, as well as coronary artery diseases and others. Given this, the search for potent CatL inhibitors is of great importance. In the search for new molecules to perform proteolytic activity regulation, salivary secretions from hematophagous animals have been an important source, as they present protease inhibitors that evolved to disable host proteases. Based on the transcriptome of the Haementeria vizzotoi leech, the cDNA of Cystatin-Hv was selected for this study. Cystatin-Hv was expressed in Pichia pastoris and purified by two chromatographic steps. The kinetic results using human CatL indicated that Cystatin-Hv, in its recombinant form, is a potent inhibitor of this protease, with a Ki value of 7.9 nM. Consequently, the present study describes, for the first time, the attainment and the biochemical characterization of a recombinant cystatin from leeches as a potent CatL inhibitor. While searching out for new molecules of therapeutic interest, this leech cystatin opens up possibilities for the future use of this molecule in studies involving cellular and in vivo models.
Reference:
LINHARES, Débora do Carmo(8753); FARIA, Fernanda; KODAMA, Roberto Tadashi; AMORIN, Adriane Michele Xavier Prado; PORTARO, Fernanda Calheta Vieira; TREVISAN-SILVA, Dilza; FERRAZ, Karla Fernanda; CHUDZINSKI-TAVASSI, Ana Maria . Novel cysteine protease inhibitor derived from the haementeria vizottoi leech: recombinant expression, purification, and characterization. Toxins, v.13, n.12, 12 p, 2022.
Access to the article on the Journal website:
https://www.mdpi.com/2072-6651/13/12/857
Cathepsin L (CatL) is a lysosomal cysteine protease primarily involved in the terminal degradation of intracellular and endocytosed proteins. More specifically, in humans, CatL has been implicated in cancer progression and metastasis, as well as coronary artery diseases and others. Given this, the search for potent CatL inhibitors is of great importance. In the search for new molecules to perform proteolytic activity regulation, salivary secretions from hematophagous animals have been an important source, as they present protease inhibitors that evolved to disable host proteases. Based on the transcriptome of the Haementeria vizzotoi leech, the cDNA of Cystatin-Hv was selected for this study. Cystatin-Hv was expressed in Pichia pastoris and purified by two chromatographic steps. The kinetic results using human CatL indicated that Cystatin-Hv, in its recombinant form, is a potent inhibitor of this protease, with a Ki value of 7.9 nM. Consequently, the present study describes, for the first time, the attainment and the biochemical characterization of a recombinant cystatin from leeches as a potent CatL inhibitor. While searching out for new molecules of therapeutic interest, this leech cystatin opens up possibilities for the future use of this molecule in studies involving cellular and in vivo models.
Reference:
LINHARES, Débora do Carmo(8753); FARIA, Fernanda; KODAMA, Roberto Tadashi; AMORIN, Adriane Michele Xavier Prado; PORTARO, Fernanda Calheta Vieira; TREVISAN-SILVA, Dilza; FERRAZ, Karla Fernanda; CHUDZINSKI-TAVASSI, Ana Maria . Novel cysteine protease inhibitor derived from the haementeria vizottoi leech: recombinant expression, purification, and characterization. Toxins, v.13, n.12, 12 p, 2022.
Access to the article on the Journal website:
https://www.mdpi.com/2072-6651/13/12/857
